𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Kinetics of intravenous metoclopramide in patients with hepatic cirrhosis

✍ Scribed by F. Albani; M. R. Tamè; R. Palma; M. Bernardi

Publisher
Springer
Year
1991
Tongue
English
Weight
276 KB
Volume
40
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

✦ Synopsis

The pharmacokinetics of metoclopramide has been studied after acute IV administration to 12 patients with hepatic cirrhosis (6 with and 6 without ascites) and 6 control subjects. The elimination half-life was significantly longer in patients (11.4 h and 9.9 h in those with and without ascites, respectively, vs 6.4 h in controls). Total plasma clearance was significantly lower in patients (0.29 and 0.36 l.kg-1.h-1 vs 0.52 l.kg-1.h-1 in controls). The differences between patients with and without ascites did not reach statistical significance. Reduction of functional hepatic blood flow in cirrhotic patients is the probable cause of the observed alteration in metoclopramide kinetics.

📜 SIMILAR VOLUMES

Cardiovascular effects of octreotide in
Cardiovascular effects of octreotide in patients with hepatic cirrhosis
✍ P. Aiden McCormick; Jason Chin; Lynda Greenslade; Stelios Karatapanis; Robert Di 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 679 KB

Octreotide is thought to reduce splanchnic and variceal blood flow with minimal effects on the systemic circulation in cirrhotic patients with portal hypertension. However, we noticed significant bradycardia in some patients immediately after administration of bolus doses of octreotide. Therefore, w

Therapy of hepatitis C: Patients with ci
Therapy of hepatitis C: Patients with cirrhosis
✍ S W Schalm; G Fattovich; J T Brouwer 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB

The management of both compensated and decompensated progressed to cirrhosis is estimated to be 20% to 30%. 1 In addition to patients who present with symptoms or signs cirrhosis caused by hepatitis C must be viewed in the context of the natural history of the disease. The prognosis of compen-of chr

Safety of hepatic resection in overweigh
Safety of hepatic resection in overweight and obese patients with cirrhosis
✍ A. Cucchetti; M. Cescon; G. Ercolani; P. Di Gioia; E. Peri; A. D. Pinna 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 2 views

## Abstract ## Background The simultaneous incremental increase in incidence of both obesity and hepatocellular carcinoma (HCC) will soon lead to more overweight and obese patients with cirrhosis needing surgery. At present, little is known about postoperative mortality and morbidity in such patie

Development of autoimmune hepatitis in p
Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis
✍ Raoul Poupon; Olivier Chazouilleres; Christophe Corpechot; Yves Chrétien 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

Primary biliary cirrhosis (PBC)-autoimmune hepatitis (AIH) overlap syndrome is a clinical entity characterized by the occurrence of both conditions at the same time in the same patient. In addition to PBC-AIH overlap syndrome, transitions from one autoimmune disease to another have been reported, bu